Saturday, March 02, 2013

Ondansetron study


I am very pleased to see the article Ondansetron in Pregnancy and Risk ofAdverse Fetal Outcomes” in the New England Journal for two reasons:

1.  Drugs generally aren’t tested on pregnant women during clinical trials, so for most drugs (and food additives: see the recent FDA warning on SimplyThick), we just have no idea whether they’re safe for pregnant women or not.

2.  This is a negative result (no difference between the women who took the drug and the control).  Many journals are biased against publishing negative results, because they’re thought to be uninteresting, but knowing that a drug is safe is actually really important, so I’m glad that it’s prominently featured in the journal and on their web site.

No comments: